Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...

A trial found six weeks of yoga improved sleep quality and reduced fatigue in people with MS, suggesting its use as a ...

The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...

Please provide your email address to receive an email when new articles are posted on . Permanent discontinuation due to treatment-emergent adverse events occurred in 12% and 10.6% of treatment groups ...

The National Institute for Health and Care Excellence (NICE) has updated its guidance on the use of cladribine (Mavenclad, Merck) for patients with rapidly evolving severe relapsing-remitting multiple ...

A small study found MS patients reported improved quality of life and reduced depression after Ocrelizumab biosimilar treatment ...

Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the relapsing-remitting (RR) disease course. This means that people have relapses -- also ...

New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine suggests that a therapy called Tolebrutinib could reduce disability progression in ...

Heidi Crayton, MD, and Maria Lopes, MD, discuss the impact of multiple sclerosis on patients, families, and caregivers, differentiate relapsing forms (relapsing-remitting and primary progressive) from ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...